Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Up 63.7% in February

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the recipient of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 122,600 shares, an increase of 63.7% from the February 13th total of 74,900 shares. Based on an average daily volume of 395,100 shares, the days-to-cover ratio is presently 0.3 days. Currently, 6.1% of the shares of the company are sold short.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp grew its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 75.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 703,384 shares of the biotechnology company’s stock after buying an additional 301,634 shares during the quarter. Sigma Planning Corp owned 1.17% of Aptose Biosciences worth $158,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Wall Street Analysts Forecast Growth

APTO has been the topic of several recent analyst reports. StockNews.com began coverage on Aptose Biosciences in a research report on Wednesday, March 5th. They issued a “sell” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Aptose Biosciences in a research report on Wednesday, February 12th. Finally, Alliance Global Partners raised shares of Aptose Biosciences to a “strong-buy” rating in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $130.00.

Aptose Biosciences Trading Down 2.4 %

Shares of NASDAQ:APTO opened at $3.69 on Monday. The firm has a market capitalization of $7.90 million, a PE ratio of -1.24 and a beta of 1.14. Aptose Biosciences has a 1-year low of $2.39 and a 1-year high of $51.61. The business’s 50 day moving average is $5.13 and its 200-day moving average is $8.04.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.